BioCentury | Jan 22, 2021
Product Development

Lilly, AbCellera mAb could enable broad deployment for COVID without taxing infusion centers

A mobile Phase III prevention study showing a COVID-19 mAb from AbCellera and Lilly reduced symptomatic cases in nursing home residents and staff highlights a strategy that could enable mass deployment without relying on centralized infusion centers. It...
BioCentury | Jan 21, 2021
Product Development

How spike mutations in SARS-CoV-2 variants affect vaccines, therapies: Data Byte

Recent papers suggest that although emerging SARS-CoV-2 variants have only minimally affected vaccine potency so far, vaccine and mAb developers need to take steps now to monitor for and counter escape...
BioCentury | Jan 12, 2021
Product Development

Lilly’s amyloid therapy not a big step forward from Biogen’s

With a more sophisticated protocol for selecting patients and positive Phase II data in hand, Eli Lilly is heading into a confirmatory trial of its Alzheimer’s therapy donanemab in an arguably stronger...
BioCentury | Jan 9, 2021

4Q20 Wrap: Stocking up

Life sciences stocks continued an upward trajectory at the end of 2020, with median gains of at least 7% in 4Q20 and at least 24% over the year across all market cap tiers. Companies valued...
BioCentury | Jan 8, 2021
Emerging Company Profile

Impact founder Hood launches Endeavor with $62M to address pulmonary diseases

Endeavor launched Thursday with $62 million from a series A financing round led by Omega Funds and Longitude Capital to treat pulmonary diseases, starting with a hedgehog pathway inhibitor in-licensed from Eli Lilly. John Hood,...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

The Trump administration’s America First policies, especially its reluctance to support life sciences companies with ties to China, may be slowing the development of medicines that could treat or prevent COVID-19. Two biotechs focused on...
BioCentury | Dec 19, 2020
Product Development

Features that differentiate four leading COVID mAbs: Data Byte

A side-by-side look at the properties of four antiviral mAbs in development for COVID-19 illuminates variations that may yield differentiated clinical profiles. Though all the candidates target the receptor-binding domain of SARS-CoV-2 spike, they differ in the...
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

Russian and AZ COVID vaccines in combo trialAstraZeneca plc (LSE:AZN; NASDAQ:AZN) will begin by year-end a clinical trial of its AZD1222, developed with the University of Oxford, in combination with the adenovirus serotype 26 (Ad26)...
BioCentury | Dec 11, 2020

AbCellera valuation tops $15B as 2020’s IPO class nears completion

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for its COVID-19 treatment to one of the year’s biggest offerings, then nearly tripled its value in the early...
BioCentury | Dec 9, 2020
Product Development

Dec. 8 COVID Quick Takes: U.K. Vaccines Taskforce to test combinations, plus advances from Clover, Lilly and India’s Serum Institute

U.K. plans to test vaccine combosThe U.K. Vaccines Taskforce will conduct a series of trials next year combining different COVID-19 vaccines, though it has not disclosed which vaccines will be included. Its year-end report stated that the availability...
Items per page:
1 - 10 of 919